FDA accepts Salix’s latest new drug application

Posted on January 31, 2014 

Salix Pharmaceuticals announced this week that the Food and Drug Administration has accepted its new drug application for Budesonide, a rectal foam used to treat patients with ulcerative colitis.

The FDA expects to issue a ruling on the application on Sept. 15.

Raleigh-based Salix sells drugs to treat gastrointestinal ailments. Earlier this year, Salix completed its $2.6 billion acquisition of the specialty drug company Santarus, which focuses on similar areas of treatment.

Staff writer David Bracken

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service